Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Rationale No studies to date have directly compared the tolerability and efficacy of smoked marijuana and oral dronabinol in HIV(+) marijuana smokers. Objectives The aim of this study was to compare dronabinol (0, 10, 20, 30 mg p.o.) and marijuana [0.0, 1.8, 2.8, 3.9% Delta(9)-tetrahydrocannabinol (THC)] in two samples of HIV(+) marijuana smokers: those with (n=15) and those without (n=15) a clinically significant loss of muscle mass ( Methods Mood, physical symptoms, self-selected food intake, cardiovascular data, and cognitive task performance were measured before and repeatedly after dronabinol and marijuana administration in eight 7-h sessions. Marijuana and dronabinol were administered in randomized order using a within-subject, staggered, double-dummy design. Results As compared to placebo, (1) marijuana (1.8, 2.8, 3.9% THC) and the lower dronabinol doses (10, 20 mg) were well tolerated (e.g., few physical symptoms, significant increases in ratings of "good drug effect") in both groups of participants; the highest dose of dronabinol (30 mg) was poorly tolerated in a subset of participants; (2) marijuana and dronabinol significantly increased caloric intake in the low bioelectrical impedance analysis (BIA) group but not in the normal BIA group; and (3) drug effects on cognitive performance were minor. Conclusions These data suggest that for experienced marijuana smokers with clinically significant muscle mass loss, both dronabinol (at acute doses at least four to eight t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Neuropsychological Performance in Long-term Cannabis Users
Pope, H. G., Gruber, A. J., Hudson, J. I., Huestis, M. A., & Yurgelun-Todd, D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.909 · Cited by 655
Prevalence of Marijuana Use Disorders in the United States: 1991-1992 and 2001-2002
Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2004) · JAMA · doi:10.1001/jama.291.17.2114 · Cited by 537
Pulmonary Hazards of Smoking Marijuana as Compared with Tobacco
WU, T.-C., Tashkin, D. P., Djahed, B., & Rose, J. E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802113180603 · Cited by 521
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., & Shepard, K. V. (1995) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(94)00117-4 · Cited by 504 · cited 3×
“For example, in non-marijuana smokers, much lower doses of dronabinol (e.g., 2.5 mg) produced confusion and anxiety ( Beal et al. 1995; Timpone et al. 1997).”
BackgroundInfluentialKotler, D., Burastero, S., Wang, J., & Pierson, R. (1996) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/64.3.489s · Cited by 472 · cited 1×
“Those less than 90% of ideal body cell mass based on HIV-validated norms were placed in the low BIA group (Kotler et al. 1996).”
MethodMarijuana and medicine: assessing the science base
(1999) · Choice Reviews Online · doi:10.5860/choice.37-2206 · Cited by 410
Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06861-9 · Cited by 406
Abstinence symptoms following smoked marijuana in humans
Haney, M., Ward, A. S., Comer, S. D., Foltin, R. W., & Fischman, M. W. (1999) · Psychopharmacology · doi:10.1007/s002130050849 · Cited by 353
Self-citationEffects of Acute Smoked Marijuana on Complex Cognitive Performance
Hart, C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00273-1 · Cited by 271
Cited by
Items 101–127 of 127
Overview of Cannabis Use, Misuse, and Addiction
Stern, C. A. J., Bertoglio, L. J., & Takahashi, R. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800213-1.00061-4 · Cited by 1
Appendix B: Quality Research, Evidence of Effectiveness of Medical Cannabis
(2018) · Journal of Nursing Regulation · doi:10.1016/s2155-8256(18)30099-1 · Cited by 1
Cohen, E. (2015) · Summit (Simon Fraser University) · Cited by 1
Cannabis (Marijuana) and Cannabinoids
Upton, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00061-3 · Cited by 2
Cannabinoids and the brain: New hopes for new therapies
Fernández‐Ruíz, J., Hernández, M., & García‐Movellán, Y. (2014) · Wiley eBooks · doi:10.1002/9781118451281.ch6 · Cited by 2
Cannabinoid mediated diuresis in mice
Chopda, G. R. (2013) · Digital Repository Service (Northeastern University) · doi:10.17760/d20196364
Roloff, A. M. (2009) · University of Minnesota Digital Conservancy (University of Minnesota)
Gestational weight gain and the association with offspring growth and obesity
Diesel, J. (2014) · D-Scholarship@Pitt (University of Pittsburgh)
Practical Aspects of Discussing Marijuana in a New Era
LeNoue, S. R., Wongngamnit, N., & Thurstone, C. (2016) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000189
Cannabis and Medicinal Properties.
Madras, B. K. (2016) · PubMed · Cited by 1
Effects of Cannabis Abstinence on Symptoms and Cognition in Major Depressive Disorder
Lucatch, A. M. (2019) · TSpace (University of Toronto)
Schleicher, E. M. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8990
Can We Change the Body Fat Distribution Phenotype? Lessons from PPAR Agonists
Punthakee, Z., & Gerstein, H. C. (2008) · CRC Press eBooks · doi:10.3109/9781420060850-18
Appendix C: References (Part I)
(2018) · Journal of Nursing Regulation · doi:10.1016/s2155-8256(18)30100-5
Targeting the endocannabinoid system in HAND
Yadav-Samudrala, B. J., & Fitting, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99744-7.00013-4
Clinical uses of cannabis and Catha edulis products
Ezzat, S. M., Abdel-Baki, P. M., Ibrahim, R. M., Elezz, D. A., Abdelaziz, M., & Salem, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95927-8.00028-1
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517185
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517173
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517164
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517176
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517179
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517167
Johnson, D. A., Funnell, M. P., Cable, T. G., Peden, D. L., McLeod, C. J., Wheeler, P. C., Bailey, S. J., Clifford, T., Heaney, L. M., & James, L. J. (2026) · Appetite · doi:10.1016/j.appet.2026.108531 · Cited by 1
Barreras de acceso al cannabis medicinal en Colombia. Una revisión narrativa
Castaño, G. A., Carrillo, S., & Malagón, R. (2025) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v54n1.119551 · Cited by 2
“Se dispone de evidencia de calidad moderada a alta a través de múltiples estudios sobre el tratamiento eficaz con cannabis para las siguientes afecciones: ⦁ Caquexia (Abrams et al. [43]; Andries et al. [44]; Haney et al. [45]; Haney et al. [46]; Timpone et al. [47]).”
Substances psychoactives : politiques et responsabilité de l'État : le point de vue des Français
Camus, J. (2013) · theses.fr (ABES) · doi:10.70675/31d7b2f5z6168z4d00z92faz559c8645bd6b · Cited by 2
Ross, J. M., Ellingson, J. M., Panchal, Z., Legget, K. T., Friedman, N. P., Schuster, R. M., Duffy, A., Olsavsky, A. K., Mikulich‐Gilbertson, S. K., Calcaterra, S. L., et al. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113315
Metadata
- Authors
- Haney, M., Rabkin, J., Gunderson, E., & Foltin, R. W.
- Affiliations
- New York State Psychiatric Institute (US)
- Corresponding author
- Haney, Margaret
- Venue
- Psychopharmacology
- Published
- 2005-03-19
- Volume
- 181
- Issue
- 1
- Pages
- 170-178
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2056047771
- Cited by
- 126
- References
- 49
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 12 · 2021: 4 · 2020: 8 · 2019: 9 · 2018: 7 · 2017: 4 · 2016: 14 · 2015: 6 · 2014: 11 · 2013: 6 · 2012: 4
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA-09236, R01DA012698, P50DA009236, DA12698)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- dronabinol, cannabis smoking, HIV, AIDS wasting, muscle mass loss, energy intake, dietary intake, mood, drug tolerability, cognitive performance, delta-9-tetrahydrocannabinol, bioelectrical impedance analysis, body cell mass
- MeSH terms
- Adult, Affect, Energy Intake, Capsules, Diarrhea, Dose-Response Relationship, Drug, Eating, Female, Headache, Heart Rate, HIV Seropositivity, Humans, Hunger, Male, Marijuana Smoking, Nausea, Psychotropic Drugs, Surveys and Questionnaires, Mental Recall, Satiety Response, Task Performance and Analysis, Dronabinol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.